A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
Amita PatnaikMichael GordonFrank TsaiKyriakos P PapadopoulosDrew RascoMuralidhar BeeramSiqing FuFilip JankuScott M HynesSushma R GundalaMelinda D WillardWei ZhangAimee Bence LinDavid S HongPublished in: Cancer chemotherapy and pharmacology (2018)
Although this study defined the LY3164530 MTD and pharmacokinetics on both schedules, significant toxicities associated with EGFR inhibition and lack of a potential predictive biomarker limit future development. Nonetheless, the results provide insight into the development of bispecific antibody therapy.